Literature DB >> 1090420

High level positive end expiratory pressure (PEEP) in acute respiratory insufficiency.

R R Kirby, J B Downs, J M Civetta, J H Modell, F J Dannemiller, E F Klein, M Hodges.   

Abstract

Twenty-eight patients developed severe, progressive acute respiratory insufficiency despite aggressive application of conventional respiratory therapy. Application of increased PEEP (18 torr or greater) resulted in a significant decrease in QA/QT. Selection of the optimal levle of PEEP for each patient required serial determinations of QA/QT and measurement of cardiovascular response. The overall survival rate was 61 percent. Acute respiratory insufficiency was a proximate cause of death in only one patient. Four of the patients (14 percent) developed a pneumothorax following institution of high PEEP therapy. Cardiac output was not affected adversely at any level of PEEP up to 32 torr (44 cm H2O). We conclude that high levels of PEEP can be therapeutic for patients with refractory respiratory failure when combined with intermittent mandatory ventilation and careful cardiovascular monitoring. As with any therapy, the optimum dose should be tailored to each patient according to his needs and response.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1090420     DOI: 10.1378/chest.67.2.156

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  47 in total

Review 1.  Did studies on HFOV fail to improve ARDS survival because they did not decrease VILI? On the potential validity of a physiological concept enounced several decades ago.

Authors:  Didier Dreyfuss; Jean-Damien Ricard; Stéphane Gaudry
Journal:  Intensive Care Med       Date:  2015-10-05       Impact factor: 17.440

Review 2.  Hypothesis: Fever control, a niche for alpha-2 agonists in the setting of septic shock and severe acute respiratory distress syndrome?

Authors:  F Petitjeans; S Leroy; C Pichot; A Geloen; M Ghignone; L Quintin
Journal:  Temperature (Austin)       Date:  2018-05-22

3.  An experimental study of different ventilatory modes in piglets in severe respiratory distress induced by surfactant depletion.

Authors:  J B Nielsen; U H Sjöstrand; E L Edgren; M Lichtwarck-Aschoff; B A Svensson
Journal:  Intensive Care Med       Date:  1991       Impact factor: 17.440

4.  The concept of "baby lung".

Authors:  Luciano Gattinoni; Antonio Pesenti
Journal:  Intensive Care Med       Date:  2005-04-06       Impact factor: 17.440

5.  Lung inflation and alveolar permeability to non-electrolytes in the adult sheep in vivo.

Authors:  E A Egan; R M Nelson; R E Olver
Journal:  J Physiol       Date:  1976-09       Impact factor: 5.182

Review 6.  New concepts in mechanical ventilation for ARDS.

Authors:  M R Lessard
Journal:  Can J Anaesth       Date:  1996-05       Impact factor: 5.063

7.  Small Airway Dysfunction Impairs Quality of Life Among Smokers With No Airflow Limitation.

Authors:  Cristina García-Quero; José Carreras; Elisabet Martínez-Cerón; Raquel Casitas; Raúl Galera; Cristina Utrilla; Isabel Torres; Francisco García-Río
Journal:  Arch Bronconeumol (Engl Ed)       Date:  2019-02-26       Impact factor: 4.872

8.  The acute respiratory distress syndrome: definitions, severity and clinical outcome. An analysis of 101 clinical investigations.

Authors:  P Krafft; P Fridrich; T Pernerstorfer; R D Fitzgerald; D Koc; B Schneider; A F Hammerle; H Steltzer
Journal:  Intensive Care Med       Date:  1996-06       Impact factor: 17.440

9.  A clinical comparison of indices of pulmonary gas exchange with changes in the inspired oxygen concentration.

Authors:  I A Herrick; L K Champion; A B Froese
Journal:  Can J Anaesth       Date:  1990-01       Impact factor: 5.063

10.  Combined effects of inversed ratio ventilation (IRV) with positive end-expiratory pressure ventilation (PEEP) on cardiorespiratory function in acute respiratory failure.

Authors:  A Sari; T Toriumi; S Yamashita; T Nonoue; S Kojima; K Kawai; A Yonei
Journal:  J Anesth       Date:  1991-04       Impact factor: 2.078

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.